Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...